The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Topic summary

Stability of BPC-157 in solution: what has been measured — one year on

This is a generated summary. It shows the 9 most-liked posts from a topic of 99, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
SO
s.ostergaardTL2 Moderator4 Mar 2026#17

Two things before anyone answers the substance.

First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.

26 likes 5mo
EM
e.mwangiTL2 Moderator17 Mar 2026#23

Oral versus injected administration claims for BPC-157: the preclinical work studied injection. Oral claims are common in supplier marketing and poorly supported by published evidence. If you are comparing orality between compounds, that is a distinction worth noting.

33 likes 4mo
IT
integrator_traceTL2Member31 Mar 2026#30

Analytical identity of BPC-157: a 15-residue peptide with an unambiguous mass (≈1419.5 Da). Identity confirmation by LC-MS is trivially easy, which means there is no excuse for an unverified identity on this compound.

31 likes 4mo
JI
j.iyerTL2 Moderator6 Apr 2026#33
k.fonseca, post #7: post #6 is right about the mechanism and I think understates the practical bit. Oral versus injected administration claims for BPC-157: the preclinical work studied injection. Oral claims are common in supplier marketing and poorly supported by published evidence. If you are comparing orality between compounds, that is a distinction… Go to post

Two things before anyone answers the substance.

First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.

31 likes in reply to #7 4mo
CG
c.grimaldiTL2 Moderator3 May 2026#47
n.ekstrom, post #10: Coming back to post #8, because the follow-up matters more than the original answer. Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive. Go to post

For anyone arriving from search engines: this subcategory discusses published preclinical work and the absence of published clinical work. It does not endorse or recommend these compounds.

29 likes in reply to #10 3mo
AV
a.villalobosTL2 Moderator20 May 2026 · edited#57

Coming back to post #55, because the follow-up matters more than the original answer.

Two things before anyone answers the substance.

First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.

32 likes 2mo
JT
j.teixeiraTL2 Moderator9 Jun 2026#69

post #68 answers the question as asked. The question underneath it is different.

Stability of BPC-157 in solution: what has been measured in published work covers specific formulations under specific conditions. Extrapolating to a reconstituted preparation in a different diluent at a different concentration is an extrapolation, acknowledged as one.

32 likes 2mo
AS
a.stephanopoulosTL3Regular29 Jun 2026#81

The distinction between "no evidence it works" and "evidence it does not work": we have the first for these compounds. That is genuinely different from the second and the distinction matters, but it also means treatment plans based on these compounds are being built on theoretical grounds, not empirical ones.

28 likes 29d
KH
ka.haddadTL2 Moderator18 Jul 2026#93
glossary_desk, post #54: This follows post #51 rather than contradicting it. Oral versus injected administration claims for BPC-157: the preclinical work studied injection. Oral claims are common in supplier marketing and poorly supported by published evidence. If you are comparing orality between compounds, that is a distinction worth noting. Go to post

Two things before anyone answers the substance.

First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.

25 likes in reply to #54 10d

Read the full topic (99 posts)

Moved from Semaglutide by s.leclerc. Category placement is not obvious from outside and getting it wrong is expected. This topic will get better answers here. The move is recorded in the public log citing R7.

Suggested topics

TopicParticipantsRepliesViewsActivity
BPC-157: what the rodent literature actually shows, and what it does not — does this still hold?
The question in the title: BPC-157: what the rodent literature actually shows, and what it does not — does this still hold? I will give what I have already checked below so nobody repeats it. I have seen…
ASBSMCSBLS+6 10 3.1k 1d
TB-500 and thymosin beta-4: the fragment versus the protein
TB-500 and thymosin beta-4: the fragment versus the protein Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a…
COGDJLDVS+107 118 22k 11mo
Oral versus injected administration claims for BPC-157
Oral versus injected administration claims for BPC-157 — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim I do not think…
RMAAMMRST+20 24 47k 4mo
Analytical identity of BPC-157: a 15-mer with a simple mass — does this still hold?
Analytical identity of BPC-157: a 15-mer with a simple mass — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SURPASS-2 ( N Engl J…
WRNDTHFBV+28 33 1.6k 1mo
Why plausible mechanism is not evidence of effect — one year on
The question in the title: Why plausible mechanism is not evidence of effect — one year on I will give what I have already checked below so nobody repeats it. Session topic: STEP 4 ( JAMA , 2021). Please read…
FNPNMBUCIL+3 7 3.6k 13mo

Related topics — sharing the tags needs a source, observational data, preprint

TopicParticipantsRepliesViewsActivity
Coming back to: A critique that turned out to be unfair, retracted by its author
A critique that turned out to be unfair, retracted by its author — setting out what I have, and where I think it stops being reliable. I have seen STEP 4 ( JAMA , 2021) cited in support of a claim I do not…
IAQLJB 2 1.3k 14mo
About the Datasets category
Community-collected datasets, their collection methods, and their limitations. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author and a…
BNOFSVPSAA+6 11 42k 12mo
Insulin combinations and hypoglycaemia risk
On the subject in the title: Insulin combinations and hypoglycaemia risk Working notes rather than a conclusion. Practical question with the units stated, because I have seen how quickly these go wrong…
VBDTRGCSMS+18 22 7.8k 13mo
[2026 update] Antibiotics and a course of something with delayed emptying
On the subject in the title: Antibiotics and a course of something with delayed emptying Working notes rather than a conclusion. Reporting something rather than asking about it, in case the pattern is useful…
NSEVABKPDT+88 97 19k 13h
Whether an aggregate is worth publishing at all: a disputed topic — does this still hold?
Whether an aggregate is worth publishing at all: a disputed topic — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. I would like to understand…
BDHFBWIBOF+14 18 3.4k 2mo